No abstract

No abstract

No abstract

Background Iodinated and gadolinium-based contrast media (ICM; GBCM) induce immediate hypersensitivity (IH) reactions. Differentiating allergic from non-allergic IH is crucial; allergy contraindicates the culprit agent for life. We studied frequency of allergic IH among ICM or GBCM reactors. Methods Patients were recruited in 31 hospitals between 2005 and 2009. Clinical symptoms, plasma histamine and tryptase concentrations and skin tests were recorded. Allergic IH was diagnosed by intradermal tests (IDT) with the culprit CM diluted 1:10, “potentially allergic” IH by positive IDT with pure CM, and non-allergic IH by negative IDT. Findings Among 245 skin-tested patients (ICM = 209; GBCM = 36), allergic IH to ICM was identified in 41 (19.6%) and to GBCM in 10 (27.8%). Skin cross-reactivity was observed in 11 patients with ICM (26.8%) and 5 with GBCM (50%). Allergy frequency increased with clinical severity and histamine and tryptase concentrations (p < 0.0001). Cardiovascular signs were strongly associated with allergy. Non-allergic IH was observed in 152 patients (62%) (ICM:134; GBCM:18). Severity grade was lower (p < 0.0001) and reaction delay longer (11.6 vs 5.6 min; p < 0.001). Potentially allergic IH was diagnosed in 42 patients (17.1%) (ICM:34; GBCM:8). The delay, severity grade, and mediator release were intermediate between the two other groups. Interpretation Allergic IH accounted for < 10% of cutaneous reactions, and > 50% of life-threatening ones. GBCM and ICM triggered comparable IH reactions in frequency and severity. Cross-reactivity was frequent, especially for GBCM. We propose considering skin testing with pure contrast agent, as it is more sensitive than the usual 1:10 dilution criteria.

Percutaneous vertebroplasty (PVP) with acrylic cement [polymethylmethacrylate (PMMA)]consists of injecting PMMA into vertebral bodies weakened by osseous lesions. The aim of PVP with PMMA is to obtain an antalgic effect by consolidation in destructive lesions of the spine. There are three major indications: vertebral angiomas, osteoporotic vertebral crush syndromes, and malignant vertebral tumors. Indications in vertebral angiomas only concern patients with aggressive clinical signs (severe pain or nervous compression) and/or aggressive radiological signs. Indications in osteoporotic vertebral crush syndromes only concern patients suffering from back pain related to one or two adjacent vertebral collapses resistant to medical treatment for several weeks. Indications in malignant vertebral tumors only concern patients suffering from severe back pain related to a destruction of the vertebral body, not involving the major part of the cortical bone. Complications of PVP occur essentially in patients with vertebral metastasis. In the great majority of cases, these complications heal under medical treatment. In patients with osteoporotic vertebral crush syndromes or vertebral angiomas, the complications are represented by the increase or onset of radiculalgias (in less than 1%), which disappear after local anesthetic injection.